Is p53 immunohistochemistry alone useful for delineating adjuvant endometrial treatment in low-middle-income countries?

Objective: Endometrial cancer (EC) treatment changed substantially with the introduction of molecular classification. Low-middle income (LMIC) countries will face barriers to including molecular classification to guide treatment. This study aims to analyse the value of p53 immunohistochemistry to delineate adjuvant treatment in FIGO stages I and II.